Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A4
- Development stage
- Phase 3
- Lead developer
- BOL Pharma
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
A4 is a specific medical cannabis oil formulation developed by Breath of Life International Pharma Ltd (BOL Pharma). It consists of a plant-derived cannabis extract diluted in medium-chain triglyceride (MCT) oil, containing a high ratio of cannabidiol (CBD) to delta-9-tetrahydrocannabinol (THC), specifically 34.8 mg of CBD and 1.7 mg of THC per 6-drop dose. The formulation is designed for sublingual administration. It has been evaluated in Phase 1 clinical trials for safety and pharmacokinetics and is being investigated for the treatment of autism spectrum disorder (ASD) and neuropathic pain. The mechanism of action involves the modulation of the endocannabinoid system, where CBD acts as a non-psychoactive cannabinoid with potential anti-inflammatory and neuroprotective effects, while THC acts as a partial agonist at CB1 and CB2 receptors.
- Other names
- Medical Cannabis oil in MCT oil (CBD 34.8 mg, THC 1.7 mg)
02
Targets
MAGE-A4 peptide-HLA-A*02:01 complexCNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on A4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A4.